Grifols (GRFS) Other Non-Current Liabilities (2010 - 2025)
Grifols (GRFS) reported Other Non-Current Liabilities of $138.5 million for Q4 2025, up 12862.92% on a YoY basis from N/an in Q4 2024, and up 12862.92% quarter-over-quarter from $1.1 million in Q4 2024.
Grifols (GRFS) Other Non-Current Liabilities (2010 - 2025) Analysis & Trends
Grifols has reported Other Non-Current Liabilities for 16 years, with the latest figure at $138.5 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Liabilities rose 12862.92% year-over-year to $138.5 million; the trailing twelve-month figure through Dec 2025 stood at $138.5 million (up 12862.92% YoY), and the FY2025 full-year result was $138.5 million, up 12862.92% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $138.5 million, up from $1.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $138.5 million in Q4 2025, with the low at $1.1 million in Q4 2024.
- Historically, Other Non-Current Liabilities has averaged $81.1 million across 5 years, with a median of $112.3 million in 2022.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities slumped 99.15% — and 2025, when it jumped 12862.92%.
- Grifols' Other Non-Current Liabilities stood at $27.6 million in 2021, then surged by 306.93% to $112.3 million in 2022, then advanced by 12.03% to $125.8 million in 2023, then tumbled by 99.15% to $1.1 million in 2024, then jumped by 12862.92% to $138.5 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $138.5 million (Q4 2025), $1.1 million (Q4 2024), and $125.8 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138.52 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Dec 31, 2023 | 125.80 Mn |
| Dec 31, 2022 | 112.29 Mn |
| Dec 31, 2021 | 27.59 Mn |
| Dec 31, 2020 | 32.51 Mn |
| Sep 30, 2020 | 661.48 Mn |
| Mar 31, 2020 | -2.10 Mn |
| Dec 31, 2019 | 8.89 Mn |
| Sep 30, 2019 | 497.08 Mn |
| Mar 31, 2019 | -550,128.37 |
| Dec 31, 2018 | 6.98 Mn |
| Sep 30, 2018 | 500.18 Mn |
| Jun 30, 2018 | 96.90 Mn |
| Mar 31, 2018 | 13.16 Mn |
| Dec 31, 2017 | 6.79 Mn |
| Jun 30, 2017 | 85.29 Mn |
| Mar 31, 2017 | 289,790.68 |
| Dec 31, 2016 | 5.53 Mn |
| Sep 30, 2016 | 97.13 Mn |